コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 patients with locally advanced unresectable pancreatic adenocarcinoma.
2 of clear cell renal cell carcinoma (RCC) and pancreatic adenocarcinoma.
3 ses with ongoing sequencing efforts in human pancreatic adenocarcinoma.
4 ncreatic juice of a patient suffering from a pancreatic adenocarcinoma.
5 ment approaches are needed for patients with pancreatic adenocarcinoma.
6 lic reprogramming is an emerging hallmark of pancreatic adenocarcinoma.
7 th patients resected for conventional ductal pancreatic adenocarcinoma.
8 ouse model of pancreatic cancer and in human pancreatic adenocarcinoma.
9 opulations arising in primary and metastatic pancreatic adenocarcinoma.
10 erapy administered in patients with resected pancreatic adenocarcinoma.
11 of matched patients with conventional ductal pancreatic adenocarcinoma.
12 adjuvant therapy-for early-stage resectable pancreatic adenocarcinoma.
13 for many diseases of the pancreas, including pancreatic adenocarcinoma.
14 cell lung cancer, head and neck cancer, and pancreatic adenocarcinoma.
15 for patients who had undergone resection for pancreatic adenocarcinoma.
16 pancreaticoduodenectomy (PD) for stage I/II pancreatic adenocarcinoma.
17 ronic pancreatitis and its relationship with pancreatic adenocarcinoma.
18 odenectomy (PD) for patients with stage I/II pancreatic adenocarcinoma.
19 use of morbidity and a known risk factor for pancreatic adenocarcinoma.
20 rrantly glycosylated in >80% of human ductal pancreatic adenocarcinoma.
21 s an important tumor marker in patients with pancreatic adenocarcinoma.
22 es with Nox4 both in PaCa cells and in human pancreatic adenocarcinoma.
23 s performed on 360 consecutive patients with pancreatic adenocarcinoma.
24 endoscopy in the diagnosis and treatment of pancreatic adenocarcinoma.
25 that influence the metastatic properties of pancreatic adenocarcinoma.
26 a signaling may promote tumor progression in pancreatic adenocarcinoma.
27 eritumoral SPARC expression in patients with pancreatic adenocarcinoma.
28 cisplatin for patients with locally advanced pancreatic adenocarcinoma.
29 in a range of human malignancies, including pancreatic adenocarcinoma.
30 te to the early spread and poor prognosis of pancreatic adenocarcinoma.
31 nt prognostic factors stratify patients with pancreatic adenocarcinoma.
32 s well as a potential therapeutic target, in pancreatic adenocarcinoma.
33 e abdominal pain resulting from unresectable pancreatic adenocarcinoma.
34 at plays an important role in the biology of pancreatic adenocarcinoma.
35 CEACAM6 is a novel biomarker for pancreatic adenocarcinoma.
36 pathologic features and clinical outcome in pancreatic adenocarcinoma.
37 be a target for therapeutic intervention in pancreatic adenocarcinoma.
38 ation and assessment of cystic precursors to pancreatic adenocarcinoma.
39 eatment and palliation of complications from pancreatic adenocarcinoma.
40 ether have value for classifying subtypes of pancreatic adenocarcinoma.
41 ovel therapeutic target for the treatment of pancreatic adenocarcinoma.
42 reproducibility of previous AJCC staging for pancreatic adenocarcinoma.
43 ery of genes involved in the pathogenesis of pancreatic adenocarcinoma.
44 havior and a potential therapeutic target in pancreatic adenocarcinoma.
45 plays a critical role in the development of pancreatic adenocarcinoma.
46 terial phase is unnecessary for detection of pancreatic adenocarcinoma.
47 ly expressed in the neoplastic epithelium of pancreatic adenocarcinoma.
48 Cancer (AJCC) system for T and N staging of pancreatic adenocarcinoma.
49 pression in an orthotopic xenograft model of pancreatic adenocarcinoma.
50 kemia cell line and in vivo against a murine pancreatic adenocarcinoma.
51 teins in patients with measurable metastatic pancreatic adenocarcinoma.
52 ection tool, in the management of resectable pancreatic adenocarcinoma.
53 evant to the pathologies of pancreatitis and pancreatic adenocarcinoma.
54 involvement is a major prognostic factor in pancreatic adenocarcinoma.
55 an 65 years and an overall increased risk of pancreatic adenocarcinoma.
56 HDAC-1, -2, -4 and -6 protein expression in pancreatic adenocarcinoma.
57 rognostic accuracy in LN-positive resectable pancreatic adenocarcinoma.
58 e/boost vaccination with GVAX and CRS-207 in pancreatic adenocarcinoma.
59 reoperative SCPN in patients with resectable pancreatic adenocarcinoma.
60 des a representative preclinical platform in pancreatic adenocarcinoma.
61 endent prognostic factor after resection for pancreatic adenocarcinoma.
62 eutic targets for both familial and sporadic pancreatic adenocarcinoma.
63 ding a genetically engineered mouse model of pancreatic adenocarcinoma.
64 the pathogenesis of cancers such as lung and pancreatic adenocarcinomas.
65 c Kras allele, we observed highly metastatic pancreatic adenocarcinomas.
66 ived from the staging algorithm for exocrine pancreatic adenocarcinomas.
67 in pancreatic tumor xenografts and clinical pancreatic adenocarcinomas.
68 enetic step in the development and growth of pancreatic adenocarcinomas.
69 rosine kinase Src is overexpressed in 70% of pancreatic adenocarcinomas.
70 have been identified in approximately 50% of pancreatic adenocarcinomas.
71 feature common to the vast majority of human pancreatic adenocarcinomas.
72 s been shown in many human tumors, including pancreatic adenocarcinomas.
73 ines established from primary and metastatic pancreatic adenocarcinomas.
74 significantly higher than reported for human pancreatic adenocarcinomas.
75 or overexpressed in gastric, esophageal and pancreatic adenocarcinomas.
76 Group 1-patients with a diagnosis of ductal pancreatic adenocarcinoma (1:1) and Group 2-a general re
77 rix) were used to profile gene expression in pancreatic adenocarcinoma (10), pancreatic cancer cell l
78 adenocarcinomas, 144 patients with familial pancreatic adenocarcinoma, 115 spouses of patients with
79 studied 250 patients with resected sporadic pancreatic adenocarcinomas, 144 patients with familial p
80 ovided the greatest benefit to patients with pancreatic adenocarcinoma: 2.31% of these patients who r
84 remains the standard therapy for metastatic pancreatic adenocarcinoma (ACA), but has limited activit
86 lastic epithelium of 90% (43 of 48) of human pancreatic adenocarcinomas analyzed by immunohistochemis
88 S: A case-control study of 841 patients with pancreatic adenocarcinoma and 754 healthy individuals fr
89 questionnaire information from 309 cases of pancreatic adenocarcinoma and 964 controls that were par
91 for the treatment of advanced or metastatic pancreatic adenocarcinoma and advanced epithelial ovaria
92 18)F-FTT uptake was seen in one subject with pancreatic adenocarcinoma and another with liver cancer.
93 npatient, or emergency department), dates of pancreatic adenocarcinoma and death, and modified Charls
94 d on cell lines derived from lung cancer and pancreatic adenocarcinoma and found a correlation betwee
95 s model to predict survival of patients with pancreatic adenocarcinoma and generated a decision model
96 appa B) is constitutively activated in human pancreatic adenocarcinoma and human pancreatic cancer ce
97 juice from 10/15 (67%) of the patients with pancreatic adenocarcinoma and in the pancreatic juice fr
99 hedgehog ligand, is abnormally expressed in pancreatic adenocarcinoma and its precursor lesions: pan
100 Cox hazard models were constructed; incident pancreatic adenocarcinoma and mortality were outcome eve
101 ients with complete gross total resection of pancreatic adenocarcinoma and no prior radiation or chem
102 d a major role in regulating the survival of pancreatic adenocarcinoma and small-cell lung cancer-der
103 emcitabine plus nab-paclitaxel in metastatic pancreatic adenocarcinoma and to provide efficacy and sa
104 GF-axis genes in 333 patients with localized pancreatic adenocarcinoma and validated the findings in
105 sought to characterize the role of EphA2 in pancreatic adenocarcinoma and, using RNA interference (R
106 nomic profiles of clonal populations from 40 pancreatic adenocarcinomas and a set of prostate adenoca
107 inase Mirk is overexpressed in many resected pancreatic adenocarcinomas and is amplified in a subset
108 of 62 samples of ovarian, breast, colon, and pancreatic adenocarcinomas and normal ovarian surface ep
109 tly expressed with a high incidence in human pancreatic adenocarcinomas and plays an important role i
110 actor (CTGF) expression is elevated in human pancreatic adenocarcinomas and some pancreatic cancer ce
111 carcinoma), CFPAC-1 (human metastatic ductal pancreatic adenocarcinoma), and HPAF-II cells (human pan
112 d methylation patterns of the TFPI-2 gene in pancreatic adenocarcinoma, and determined its role in tu
113 these drugs, others such as prostate cancer, pancreatic adenocarcinoma, and melanoma are resistant.
115 pression has been reported in 53%-89% of all pancreatic adenocarcinomas, and the expression level of
119 atients diagnosed as having T1 through T3 M0 pancreatic adenocarcinoma between January 1, 2004, and D
120 atients undergoing pancreatoduodenectomy for pancreatic adenocarcinoma between January 1, 2006 and De
121 ents who underwent pancreatoduodenectomy for pancreatic adenocarcinoma between October 2001 and June
122 d that not only is MIF induced by hypoxia in pancreatic adenocarcinoma but MIF is also necessary for
123 ribed increased prevalence of these cells in pancreatic adenocarcinoma, but it remains unclear what m
124 s patient survival rates after resection for pancreatic adenocarcinoma, but the optimal duration and
126 ngiography in the preoperative evaluation of pancreatic adenocarcinoma by using surgical findings as
127 non-small-cell lung carcinoma and another of pancreatic adenocarcinoma--by assessing responses to exi
128 Our results suggest that HPR1 expressed in pancreatic adenocarcinomas can suppress the proliferatio
133 f either 250,000 cells of the transplantable pancreatic adenocarcinoma cell line Pan02 (cancer) or ph
135 the copy number alterations in a panel of 24 pancreatic adenocarcinoma cell lines and 13 primary tumo
136 se inhibitor, suppresses the growth of human pancreatic adenocarcinoma cell lines and that this growt
137 ucin protein MUC4 is aberrantly expressed in pancreatic adenocarcinoma cell lines and tissues but is
142 ole for T1172 of L1 in regulating aspects of pancreatic adenocarcinoma cell phenotype and suggest the
143 d the anti-cancer effect of PSM and PSB over pancreatic adenocarcinoma cells and glioblastoma cells.
144 C4 with the receptor tyrosine kinase HER2 in pancreatic adenocarcinoma cells by reciprocal coimmunopr
146 st demonstrated that breast cancer cells and pancreatic adenocarcinoma cells generated micromolar lev
148 that COLXV significantly reduces invasion of pancreatic adenocarcinoma cells through a collagen I (CO
150 ble silencing of HMGA1 in MiaPaCa2 and PANC1 pancreatic adenocarcinoma cells was achieved by transfec
151 ant phenotype, CEACAM6-overexpressing Capan2 pancreatic adenocarcinoma cells were established by stab
152 sociated with gemcitabine chemoresistance in pancreatic adenocarcinoma cells, and that suppression of
153 Previously we have shown that in AsPC-1 pancreatic adenocarcinoma cells, insulin-like growth fac
157 (CEA) is highly expressed on the surface of pancreatic adenocarcinoma cells; we investigated the eff
159 inding of high levels of SPAG1 expression in pancreatic adenocarcinoma compared to normal pancreatic
160 tially expressed in chronic pancreatitis and pancreatic adenocarcinoma compared with normal pancreas.
161 tion was identified in 4.1% of patients with pancreatic adenocarcinoma compared with only 1.1% of can
162 minor alleles at R415Q had decreased risk of pancreatic adenocarcinoma compared with those who had tw
163 hat BNIP3 was down-regulated in nine of nine pancreatic adenocarcinomas compared with normal pancreas
164 est that mutational inactivation of RNF43 in pancreatic adenocarcinoma confers Wnt dependency, and th
165 external patient cohort from a retrospective pancreatic adenocarcinoma database at Massachusetts Gene
166 The nomogram was created from a prospective pancreatic adenocarcinoma database that included 555 con
167 1 gene targets in small-cell lung cancer and pancreatic adenocarcinoma-derived cell lines compared wi
168 overall survival in patients with metastatic pancreatic adenocarcinoma for whom gemcitabine-based che
169 2 and May 2014, 137 patients with metastatic pancreatic adenocarcinoma for whom gemcitabine-based che
170 stromal fibroblasts adjacent to infiltrating pancreatic adenocarcinomas frequently express SPARC.
171 >/=18 years) with newly diagnosed metastatic pancreatic adenocarcinoma from the Comprehensive Cancer
172 r findings confirm the importance of RRM2 in pancreatic adenocarcinoma gemcitabine chemoresistance.
173 ng patients with locally advanced metastatic pancreatic adenocarcinoma, gemcitabine has been shown to
175 the magnitude of the difference between the pancreatic adenocarcinoma group and the control group wa
181 ients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma have been prospectively follow
182 spirin and non-aspirin NSAID use and risk of pancreatic adenocarcinoma in 141,940 participants from t
184 nd adiposity duration and gain with incident pancreatic adenocarcinoma in the NIH-AARP Diet and Healt
185 pport for the widely accepted model of human pancreatic adenocarcinoma in which activated KRAS serves
187 rom 2004 to 2008 involving 973 patients with pancreatic adenocarcinoma (including 259 diabetic patien
188 udy, we demonstrated that HPR1 expression in pancreatic adenocarcinomas inversely correlated with the
193 c alteration found in premalignant stages of pancreatic adenocarcinoma is K-ras oncogene point mutati
199 c K-RAS mutations are found in virtually all pancreatic adenocarcinomas, making the RAS pathway an id
203 verexpressed in several carcinomas including pancreatic adenocarcinoma, modulates cancer cell metabol
204 atic intraepithelial neoplasia (n = 80), and pancreatic adenocarcinoma (n = 67) showed a significant
206 unique and reliable contrast agent targeting pancreatic adenocarcinoma, new multifunctional nanoparti
207 patients had metastatic or locally advanced pancreatic adenocarcinoma, no uncontrolled hypertension
208 atabase was used to test the validity of the pancreatic adenocarcinoma nomogram established at Memori
210 Between 1994 and 2006, 184 incident cases of pancreatic adenocarcinoma occurred (follow-up to 11.7 ye
212 f 19 patients who had curative resection for pancreatic adenocarcinoma of the uncinate process were r
213 patients underwent resection for stage I-III pancreatic adenocarcinoma of which 23.2% had at least 1
215 ve cohort study, 1122 participants developed pancreatic adenocarcinoma over 4.2 million person-years.
219 CHD5 expression in 80 patients with resected pancreatic adenocarcinoma (PAC) by immunohistochemical a
223 s detected in 73% of xenografts derived from pancreatic adenocarcinoma patients and 71% of pancreatic
224 dictive value of hENT1 levels in a cohort of pancreatic adenocarcinoma patients from the large prospe
225 Cancer Data Base was queried for T1-3N0-1M0 pancreatic adenocarcinoma patients who underwent PD.
227 described GIPC expression in different human pancreatic adenocarcinoma (PCA) cell lines and we examin
230 cells (CPNI) is found in most patients with pancreatic adenocarcinomas (PDA), prostate, or head and
232 trial, FOLFIRINOX is effective in metastatic pancreatic adenocarcinoma (PDAC), making it a rational c
233 motherapy enhanced drug uptake and effect in pancreatic adenocarcinoma (PDAC), notorious for having p
240 re being applied to primary cells from human pancreatic adenocarcinomas propagated in nude mice.
241 Forty-eight patients with locally advanced pancreatic adenocarcinoma received gemcitabine (30 mg/m2
243 ic adenocarcinoma), and HPAF-II cells (human pancreatic adenocarcinoma), respectively) with CFPAC-1 c
244 when compared with chronic pancreatitis and pancreatic adenocarcinoma, respectively, and although a
248 ysregulated in both chronic pancreatitis and pancreatic adenocarcinoma, several proteins were identif
249 portantly, we observed downregulation of the pancreatic adenocarcinoma signaling pathway in MYB-silen
250 lly overexpressed in 16 of 17 (94%) clinical pancreatic adenocarcinoma specimens compared with the su
255 ppaB and GDF-15 in epithelial ducts of human pancreatic adenocarcinoma supports the importance of thi
256 l, 3.5-136.5; P < 0.001) more likely to have pancreatic adenocarcinoma than patients with levels <20
257 o discern the regulatory role(s) of NRP-1 in pancreatic adenocarcinoma that lack these coreceptors, w
258 t inhibit tumor growth, and, specifically in pancreatic adenocarcinoma, the role of CCR5 in the homin
259 vel role for Reg3beta as a tumor promoter in pancreatic adenocarcinoma through the regulation of tumo
260 had little to offer patients with inoperable pancreatic adenocarcinoma; thus, many patients seek alte
261 ion was assessed immunohistochemically on 70 pancreatic adenocarcinoma tissue specimens and was stati
263 pproval rates varied from 0% (zero of 45) in pancreatic adenocarcinoma to 34.8% (24 of 69) for colon
264 rentially expressed proteins in six cases of pancreatic adenocarcinoma, two normal adjacent tissues,
266 nine patients suspected of having resectable pancreatic adenocarcinoma underwent triple-phase multi-d
267 ells inhibited secretion of a protein called pancreatic adenocarcinoma up-regulated factor (PAUF) but
271 of pancreatic cancer xenografts and primary pancreatic adenocarcinomas, was more likely in older pat
272 sing oncogenic Kras-driven GEMMs of lung and pancreatic adenocarcinoma, we recently showed that these
273 Previously treated patients with metastatic pancreatic adenocarcinoma were randomly assigned at a ra
274 unresectable locally advanced or metastatic pancreatic adenocarcinoma were randomly assigned to rece
276 The records of 156 consecutive patients with pancreatic adenocarcinoma were retrospectively evaluated
277 atients with locally advanced and metastatic pancreatic adenocarcinoma were treated with 2,200 mg/m2
278 Chemotherapy-naive patients with metastatic pancreatic adenocarcinoma were treated with a combinatio
279 ing a xenograft model in which primary human pancreatic adenocarcinomas were grown in immunocompromis
280 lood loss were lower after training and more pancreatic adenocarcinomas were resected (7 [10%] vs 28
281 Integrin alpha6beta4 is up-regulated in pancreatic adenocarcinomas where it contributes to carci
282 etastasis in an autochthonous mouse model of pancreatic adenocarcinoma-whereas conditional knockout o
283 aB is constitutively activated in most human pancreatic adenocarcinoma, which is a deadly malignancy
284 receptor 1 (NTR1) is overexpressed in ductal pancreatic adenocarcinoma, which is still one of the dea
287 se To test the hypothesis that patients with pancreatic adenocarcinoma who otherwise are viewed to ha
288 reviewed to identify patients with invasive pancreatic adenocarcinoma who underwent pancreatectomy w
289 nes on overall survival of 378 patients with pancreatic adenocarcinoma who were treated at University
291 rane mucin, which is aberrantly expressed in pancreatic adenocarcinoma with no detectable expression
292 a biologic rationale to treat patients with pancreatic adenocarcinoma with the nontoxic phytochemica
293 could reveal protein biomarkers specific to pancreatic adenocarcinoma, with probes available for ear
299 omal elements into expanding patient-derived pancreatic adenocarcinoma xenografts, establishing the i
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。